Form 4: ADMA Biologics COO Kaitlin Kestenberg-Messina Reports Stock Transactions
SEC Form 4
Kaitlin Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reported the acquisition and disposition of common stock and derivative securities on August 30, 2024.
Summary
- On August 30, 2024, Kaitlin Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, filed a Form 4 detailing changes in beneficial ownership.
- The transactions included the acquisition of common stock through option exercises at prices of $2.35, $2.59, $5.94, and $4.72.
- She also disposed of 24,150 shares of common stock at a weighted average price of $16.8965, with prices ranging from $16.72 to $17.02.
- Following these transactions, Kestenberg-Messina beneficially owns 449,088 shares of common stock.
- The reported holdings include unvested RSUs and shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company insider. The mix of option exercises and stock sales doesn't strongly indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities and sentiment regarding the company's stock.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of a key company executive.
Key Dates
| Date | Description |
|---|---|
| 02/25/2021 | Options granted on February 25, 2021, vesting over four years. |
| 09/28/2021 | RSUs granted on September 28, 2021, vesting on a schedule of 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024. |
| 03/07/2022 | RSUs granted on March 7, 2022, vesting in equal quarterly installments over four years. |
| 03/06/2023 | RSUs granted on March 6, 2023, vesting in equal quarterly installments over four years. |
| 07/24/2023 | RSUs granted on July 24, 2023, vesting in equal quarterly installments over four years. |
| 04/01/2024 | RSUs granted on April 1, 2024, vesting in equal quarterly installments over four years. |
| 08/30/2024 | Date of the reported transactions: acquisition and disposition of ADMA Biologics stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.